December 6, 2007 -- At the ChinaBio® Investor’s Forum 2007 Greg B. Scott, Executive Editor of ChinaBio® Today, said investment continues to grow in the health care and biotech sectors, though it remains far behind the investment levels of the US. “Bio-tech and health care venture capital investment has grown by 19% to $50 million this year in China, and the average deal has nearly doubled to $10 million,” Scott said, adding that angel investment is very small in China. “In contrast, the life science industry in the United States receives about $2 billion per year in venture capital investment, a figure that is roughly matched by the amount of angel investment in the industry,” he said. Other observers weighed in with their own takes on the state of biopharma in China. More details...
